Short-acting insulin market to cross $9b by 2030

Key drivers include technological advancements and evolving healthcare policies.

The global market for short-acting insulin is projected to cross $9b by 2030, driven by the rising prevalence of diabetes, said DelveInsight.

The sector’s expansion is also driven by advancements in technology and evolving healthcare policies.

“The development of insulin analogues and improved delivery mechanisms, such as insulin pumps and pens, has enhanced the efficacy and convenience of insulin therapy,” the report said.

In addition, innovations in insulin formulations and delivery systems are expected to expand the range of options available to patients.

Meanwhile, governments and health organisations are focusing on cost control and diabetes management guidelines, which can affect insulin pricing and reimbursement policies. 

Possible changes in reimbursement rates or new regulations for insulin approvals may influence market dynamics and competitive strategies.

“As the landscape evolves, stakeholders will need to navigate a complex environment of innovation, competition, and regulatory changes to effectively meet the needs of patients and healthcare systems,” the report added.